Dan Monahan will lead the commercialization strategy across Amylyx’ product portfolio, beginning with avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor ...

After raising questions surrounding dosing levels, the FDA has freed Amylyx’s early-stage amyotrophic lateral sclerosis (ALS) ...

Amylyx Pharmaceuticals named Dan Monahan as its chief commercial officer. 1 According to a press release, he is assuming the role in time to oversee the commercialization of avexitide, a GLP-1 ...

Amylyx Pharmaceuticals has named Dan Monahan as chief commercial officer, positioning an exec who led the U.S. commercialization of Rexulti to oversee the planned launch of a GLP-1 receptor ...

Darktrace has announced its first acquisition since its recent takeover by Thoma Bravo in October, as it focuses on ...

AWS and Microsoft partner Darktrace has appointed Dan Monahan as their new SVP for its global partner organisation. Monahan joins the Cambridge-headquartered company with over 25 years of experience ...

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the appointment of Dan Monahan as Chief Commercial Officer. Mr. Monahan will also join the Company’s Leadership ...

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the appointment of Dan Monahan as Chief Commercial Officer. Mr. Monahan will also join the Company ...

Amylyx (AMLX) Pharmaceuticals announced the appointment of Dan Monahan as Chief Commercial Officer. Mr. Monahan will also join the Company’s Leadership Team. Mr. Monahan joined Amylyx in January ...

Dan Monahan will lead the commercialization strategy across Amylyx’ product portfolio, beginning with avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) ...